Advertisement
Dr. Reddy's
Subscribe to Dr. Reddy's

The Lead

Dr. Reddy’s Announces Senior Level Changes

May 14, 2014 8:03 am | News | Comments

Dr. Reddy’s Laboratories Ltd. today announced that its Board of Directors has decided to have separate roles of the Chairman of the Company and the Managing Director and CEO.             

Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections

February 24, 2014 8:01 am | News | Comments

Cellceutix Corporation has selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of...

FDA Approves First Generic Versions of Antidepressant Drug Cymbalta

December 11, 2013 4:17 pm | News | Comments

The FDA has approved the first generic versions of Cymbalta (duloxetine delayed-release capsules...

Dr. Reddy’s Announces the Approval of Azacitidine for Injection

September 17, 2013 8:10 am | News | Comments

Dr. Reddy’s Laboratories announced today that Azacitidine for Injection 100 mg/vial, a...

View Sample

FREE Email Newsletter

Dr. Reddy's Labs Fourth Quarter Net Income Rises 67%

May 15, 2013 8:45 am | News | Comments

Dr. Reddy's Laboratories Ltd. said Tuesday its net income climbed 67 percent in the fiscal fourth quarter. The company said it earned 5.7 billion rupees ($104 million), or 60 cents per U.S. share. Its revenue grew 26 percent to 33.4 billion rupees ($611 million)

Dr. Reddy’s to Relocate North America Headquarters and Establish R&D Center in Princeton, NJ

April 9, 2013 10:26 am | News | Comments

Dr. Reddy’s Laboratories today announced plans to relocate their North America Headquarters and establish a R&D Center in Princeton, New Jersey. Dr. Reddy’s anticipates relocation to the office facility at 107 College Road East by the end of the summer of 2013 after the renovations to the facility are completed.

Dr. Reddy’s Launches Zenatane™

March 29, 2013 7:55 am | News | Comments

Dr. Reddy’s Laboratories announced today that it has launched Zenatane™ (Isotretinoin Capsules USP) in 20 mg and 40 mg, a therapeutically equivalent generic version of Accutane® (Isotretinoin Capsules USP) in the US market on March 28, 2013 following the approval by the United States Food & Drug Administration (USFDA)

Advertisement

Dr. Reddy's Fiscal 3Q Profit Sinks 26%

February 14, 2013 1:36 pm | by The Associated Press | News | Comments

Dr. Reddy's Laboratories Ltd. said Thursday its fiscal third-quarter earnings fell 26 percent compared to the same quarter last year, when a generic version of the antipsychotic Zyprexa boosted its North American sales. The Indian company reported net income of $69 million, or 40 cents per share, in the three months that ended Dec. 31.

Dr. Reddy’s Announces the Appointment of CFO and Head for North America Business

November 27, 2012 3:42 am | News | Comments

Dr. Reddy’s Laboratories Ltd. today announced that Umang Vohra, who was the CFO of the company for the past four years, will take over the role of Executive Vice-President and Head of North America Generics Business from January 2013.  

Dr. Reddy's Laboratories Ltd. and Merck Serono Announce Collaboration to Develop and Commercialize Biosimilars

June 6, 2012 4:02 am | News | Comments

Dr. Reddy's Laboratories Ltd. and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions.  

Dr. Reddy's, JB Chemicals Scrap Proposed $34.85 Million Deal

September 27, 2011 6:40 am | by NASDAQ via NewsPoints Desk | News | Comments

Dr. Reddy's Laboratories said Monday it has terminated a proposed deal to buy J.B. Chemicals & Pharmaceuticals' prescription products business in Russia and the Commonwealth of Independent States, as reported on NASDAQ.  

FDA OKs Dr. Reddy's Generic Version of Arixtra

July 13, 2011 10:53 am | News | Comments

Federal regulators approved a generic version of a blood-clot treatment made by Dr. Reddy's Laboratories, the company said Wednesday.

AstraZeneca and POZEN File Patent Infringement Lawsuit Against Dr. Reddy's

April 25, 2011 5:09 am | News | Comments

POZEN Inc. and AstraZeneca have filed a lawsuit against Dr. Reddy's Laboratories (Dr. Reddy's) in the United States District Court for the District of New Jersey, for infringement of U.S. Patent No. 6,926,907 relating to VIMOVO(TM) (naproxen / esomeprazole magnesium) delayed-release tablets.

Advertisement
X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading